Welcome to the August issue of The Highlight

The August issue of The Highlight features a cover story by Dylan Scott on the persistent stigma surrounding GLP-1 drugs like Ozempic, Wegovy, and Mounjaro, despite their popularity. Other articles include Elizabeth Weingarten on tolerating uncertainty, Marina Bolotnikova on rent control, and Sara Herschander on the coming AI wealth boom.

GLP-1 drugs like Ozempic, Wegovy, and Mounjaro have been wildly successful. But as popular as they are, Americans still have very negative feelings about the people using them. In this month’s Highlight cover story, Dylan Scott explains why ‘Ozempic stigma’ hasn’t gone away, how it’s impacting GLP-1 users, and whether it could begin to fade as more and more people take the drugs. Also in this issue: How to tolerate uncertainty. What rent freezes could mean for renters. Good news about declining road deaths. And the coming AI wealth boom. Welcome to the August issue of The Highlight By Shayla Love By Bryan Walsh The one thing Ozempic still can’t fix By Dylan Scott Coming August 4 How to tolerate uncertainty in a world that’s full of it By Elizabeth Weingarten Coming August 5 The truth about rent control By Marina Bolotnikova Coming August 5 Rise of the AI-ristocracy By Sara Herschander Coming August 6 See More: